<DOC>
	<DOCNO>NCT00813904</DOCNO>
	<brief_summary>The objective study assess immunogenicity safety recombinant Thrombin ( rThrombin ) patient prior rThrombin exposure .</brief_summary>
	<brief_title>Immunogenicity Safety Study rThrombin Surgical Hemostasis</brief_title>
	<detailed_description>The safety , immunogenicity , efficacy rThrombin evaluate Phase 2 Phase 3 study follow surgical indication : spinal surgery , major hepatic resection , peripheral arterial bypass ( PAB ) surgery , arteriovenous ( AV ) graft formation hemodialysis access , skin graft surgery follow burn injury . Limited data rThrombin reexposure currently exist . This study assess immunogenicity safety rThrombin participant undergo surgical procedure topical rThrombin application plan previously receive rThrombin Phase 3 clinical trial prior spine , AV graft formation , PAB surgical procedure .</detailed_description>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Previous enrollment ZymoGeneticssponsored Phase 3 study recipient treatment rThrombin study recipient commerciallyavailable rThrombin prior spine , arteriovenous graft formation , peripheral artery bypass surgical procedure Age 18 year old time consent Bleeding indicating treatment rThrombin course surgical procedure Signed informed consent document approve institutional review board independent ethic committee Currently undergoing procedure require cardiopulmonary bypass involve aortic arch Known hypersensitivity rThrombin product component Currently undergo surgical procedure use thrombincontaining hemostatic agent plan Medical , social , psychosocial factor , opinion investigator , could affect participant 's safety compliance study procedure Treatment experimental agent within 30 day study enrollment treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>